Bill & Melinda Gates Medical Research Institute

ACTIVE

1 Kendall Sq Ste B6301, 马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.gatesmri.orgPrivate101–250 employeesEstablished: 2017-01-01

Clinical Trials

3 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2017

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

43.8%

Phase 2

37.5%

Phase 3

12.5%

Trial Status Distribution

Active, not recruiting

12.5%

Completed

43.8%

Not yet recruiting

6.3%

Recruiting

6.3%

Terminated

25.0%

Withdrawn

6.3%

Clinical Trials

Trials sponsored by this organization (16)

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Phase 1

Completed

interventional

Mar 2025125 participants

A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11

Phase 1

Recruiting

interventional

Dec 2024124 participants

A Phase 2b/c, Multi-Arm, 2-Stage, Duration Randomized Trial of the Efficacyand Safety of Two to Four Months Treatment with Regimens Containing Bedaquiline, OPC-167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults with Pulmonary Tuberculosis.

Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults

Phase 3

Active, not recruiting

interventional

Mar 202420,080 participants

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

Phase 1

Completed

interventional

Aug 202363 participants

Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

Phase 2

Terminated

interventional

Jul 202393 participants

Impact of Bi-26 Supplementation on Weight Gain in Underweight Infants

Phase 3

Terminated

interventional

Jul 202340 participants

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Phase 1

Completed

interventional

Feb 2023119 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations